Hyung Ah Jo

Prof. Hyung Ah Jo

Department of Internal Medicine, Inje University College of Medicine, Ilsan-Paik Hospital
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
JPJung Tak Park
Jung Tak Park
HLHajeong Lee
Hajeong Lee
YKYoun Kyung Kee
Youn Kyung Kee
SPSeokwoo Park
Seokwoo Park
HOHyung Jung Oh
Hyung Jung Oh
BCByeol Na Choi
Byeol Na Choi

30 June 2018 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
SPSehoon Park
Sehoon Park
SLSoojin Lee
Soojin Lee
HJHyung Ah Jo
Hyung Ah Jo
KHKyungdo Han
Kyungdo Han
YKYaerim Kim
Yaerim Kim
DKDong Ki Kim
Dong Ki Kim
Sehoon Park, Soojin Lee, Hyung Ah Jo, Kyungdo Han, Yaerim Kim, Jung Nam An, Kwon Wook Joo, Chun Soo Lim, Yon Su Kim, Hyeongsu Kim, and Dong Ki Kim. Kidney Research and Clinical Practice 2018;37:119-29. https://doi.org/10.23876/j.krcp.2018.37.2.119

1 December 2016 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
HJHyung Ah Jo
Hyung Ah Jo
JKJoo-Young Kim
Joo-Young Kim
SYSeung Hee Yang
Seung Hee Yang
SHSeung Seok Han
Seung Seok Han
KJKwon Wook Joo
Kwon Wook Joo
DKDong Ki Kim
Dong Ki Kim
Interleukin-6 (IL6) is an important regulator of cellular hypertrophy through the gp130/Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway. We tested the hypothesis that IL6 and its downstream gp130/JAK2/STAT3 pathway participated in high glucose (HG)-induced podocyte hypertrophy. IL6 levels in the media and lysates of podocytes were measured by enzyme-linked immunosorbent assay. Western blots were performed to determine the protein expression levels of gp130/JAK2/STAT3 among podocytes cultured with normal glucose (NG), NG + mannitol, NG + recombinant IL6, HG, and HG + IL6-neutralizing antibodies (IL6NAb). Immunoprecipitation was examined to determine whether gp130 interacted with JAK2 in response to HG or IL6. Podocyte hypertrophy was verified using protein/cell counts and flow cytometry. IL6 levels were significantly increased in the media and lysates of podocytes cultured in HG compared with the NG groups. The nuclear phospho-STAT3/STAT3 ratio was increased by HG and NG + IL6 and was attenuated in the HG + IL6NAb groups, indicating that nuclear STAT3 was activated following JAK2 and cytosolic STAT3 activation in response to IL6 secreted by HG-stimulated podocytes. Immunoprecipitation showed increased phospho-JAK2 recruitment to gp130 in the HG and NG + IL6 groups, and the addition of IL6NAb in the HG group significantly abrogated these increases. Podocyte hypertrophy was significantly increased in the HG and NG + IL6 compared with the NG condition and was diminished by the addition of IL6NAbs to the HG group. IL6 might play a prominent role in the local activation of JAK2/STAT3 in podocyte hypertrophy under HG conditions. In vivo studies examining this pathway are warranted.

1 May 2017 in Experimental Cell Research
Verified
Journal Article
Closed access
SYSeung Hee Yang
Seung Hee Yang
JCJin Woo Choi
Jin Woo Choi
DHDongeun Huh
Dongeun Huh
HJHyung Ah Jo
Hyung Ah Jo
SKSejoong Kim
Sejoong Kim
DKDong Ki Kim
Dong Ki Kim

16 April 2014 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MHMiyeun Han
Miyeun Han
HPHayne Park
Hayne Park
HKHyunsuk Kim
Hyunsuk Kim
HJHyung Ah Jo
Hyung Ah Jo
HHHyuk Huh
Hyuk Huh
CACurie Ahn
Curie Ahn
The role of hyperuricemia in disease progression of autosomal dominant polycystic kidney disease (ADPKD) has not been defined well. We investigated the association of serum uric acid (sUA) with renal function and the effect of hypouricemic treatment on the rate of renal function decline. This is a single-center, retrospective, observational cohort study. A total of 365 patients with ADPKD who had estimated glomerular filtration rate (eGFR) ≥ 15 mL/min/1.73 m2 and who were followed up for > 1 year were included in our analysis. Hyperuricemia was defined by a sUA level of ≥ 7.0 mg/dL in male and ≥ 6.0 mg/dL in female or when hypouricemic medications were prescribed. Hyperuricemia was associated with reduced initial eGFR, independent of age, sex, hypertension, albuminuria, and total kidney volume. During a median follow-up period of over 6 years, patients with hyperuricemia showed a faster annual decline in eGFR (−6.3% per year vs. −0.9% per year, p = 0.008). However, after adjusting for age, sex, hypertension and initial eGFR, sUA was no longer associated with either annual eGFR decline or the development of ESRD. Among 53 patients who received hypouricemic treatment, the annual eGFR decline appeared to be attenuated after hypouricemic treatment (pretreatment vs. posttreatment: −5.3 ± 8. 2 vs. 0.2 ± 6.2 mL/min/1.73 m2 per year, p = 0.001 by Wilcoxon signed-rank test). Although hyperuricemia was associated with reduced eGFR, it was not an independent factor for renal progression in ADPKD. However, the correction of hyperuricemia may attenuate renal function decline in some patients with mild renal insufficiency.

14 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SHSeung Seok Han
Seung Seok Han
SYSeung Hee Yang
Seung Hee Yang
HJHyung Ah Jo
Hyung Ah Jo
YOYun Jung Oh
Yun Jung Oh
MPMinkyoung Park
Minkyoung Park
DKDong Ki Kim
Dong Ki Kim
BAFF and APRIL expression as an autoimmune signature of membranous nephropathy BAFF and APRIL expression as an autoimmune signature of membranous nephropathy